Idorsia is cutting up to 270 jobs globally, primarily in research and development, as part of cost-saving measures amid ongoing financial struggles. The Basel-based pharmaceutical company has also entered exclusive negotiations for worldwide rights to its blood pressure drug Aprocitentan, expected to yield $35 million. Following the announcement, Idorsia's stock rose by 7%, although it remains down 64% since January, currently valued at CHF 0.81.